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Abstract
’Gut health’ is a term increasingly used in the medical
literature and by the food industry. It covers multiple
positive aspects of the gastrointestinal (GI) tract, such
as the effective digestion and absorption of food, the
absence of GI illness, normal and stable intestinal
microbiota, effective immune status and a state of
well-being. From a scientific point of view, however, it
is still extremely unclear exactly what gut health is,
how it can be defined and how it can be measured.
The GI barrier adjacent to the GI microbiota appears
to be the key to understanding the complex
mechanisms that maintain gut health. Any
impairment of the GI barrier can increase the risk of
developing infectious, inflammatory and functional GI
diseases, as well as extraintestinal diseases such as
immune-mediated and metabolic disorders. Less clear,
however, is whether GI discomfort in general can also
be related to GI barrier functions. In any case,
methods of assessing, improving and maintaining gut
health-related GI functions are of major interest in
preventive medicine.
Background
In recent times, the term ‘gut health’ has become
increasingly popular, as is evident by its more frequent
use in the scientific literature and in the food industry
[1]. In contrast to the medical understanding of the
Western world, where gut issues are considered rather
taboo, gut health is a central theme in Asian medicine,
which recognises the abdomen as the location of
the soul. “Honoured middle” (onaka) and “centre of
the spiritual and physical strength” (hara) are how the
Japanese describe our largest organ, the intestine, which
for many Europeans is barely more than a simple diges-
tive system which simply has to function [2]. On the
other hand, gut health that is more than just a positive
gut feeling is now also increasingly recognised in the
Western world as a desirable aim and an important phy-
siological condition required for overall good health.
There may be two reasons for this. First, a growing
number of people do not enjoy good gut health, as is
indicated by the high prevalence of functional and
organic gastrointestinal (GI) diseases in the Western
world. Second, marketing professionals have discovered
this concept for their own specific goals [1,3]. However,
from a scientific point of view, it is still very unclear
what gut health is, how it can be defined and how it can
be measured. In the present article, current knowledge
of gut health is summarised. Particular emphasis is
given to the definition of the term, the underlying
mechanisms, how to assess it and how to maintain it.
Moreover, the possible impact of gut health for future,
prevention-oriented medicine, as well as the need to
increase understanding of this condition and to maintain
it, is discussed.
Discussion
Definition of gut health
The expression ‘gut health’ lacks clear definition in the
scientific literature, although it has been used repeatedly
in human medicine [4-7] and in animal health [8,9].
According to the World Health Organisation (WHO)
definition of ‘health’ from 1948, which proposes a posi-
tive definition instead of ‘the absence of diseases’,o n e
might define gut health as a state of physical and mental
well-being in the absence of GI complaints that require
the consultation of a doctor, in the absence of indica-
tions of or risks for bowel disease and in the absence of
confirmed bowel disease. Although the WHO defines
health as being more than absence of disease, prevention
or avoidance of disease is surely part of our understand-
ing of health. Actually, gut health comprises a healthy
upper and lower GI tract, although the term might sug-
gest that it is restricted to the lower GI tract. However,
other abdominal organs, such as the liver, pancreas,
spleen or kidney, are usually not associated with gut
health and therefore are not discussed here.
This definition covers the viewpoint of the potentially
afflicted individual, who expects a largely symptom-free
status that, at the very least, does not require consultation
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who must bear in mind the potential risks of bowel dis-
eases, particularly malignant bowel disease, even in the
absence of any complaints by the patient. This definition,
however, is based on exclusions and on more or less sub-
jective criteria [10].
On the basis of the results of discussions within a
scientific committee working on gut health issues, five
major criteria have been defined that might form the
basis for a positive and more objective definition of gut
health (Table 1). The criteria could be confirmed in a
questionnaire performed in a representative Western
population group (SCB, unpublished work).
The relevance of gut health is underlined by the fact
that the list of intestinal complaints that prompts an
individual to consult a doctor is long, and such com-
plaints are very common in the general population.
They include symptoms associated with functional dys-
pepsia and irritable bowel syndrome (IBS) and comprise
flatulence, bloating, regurgitation, heartburn, nausea,
vomiting, constipation, diarrhoea, food intolerance,
incontinence, abdominal pain and cramps, loss of appe-
tite, weight loss and blood in stools. In most cases, such
symptoms reflect more or less harmless diseases that
might affect quality of life but not mortality. Some of
the symptoms, however, such as anorexia, unintended
weight loss, dysphagia, continuing vomiting, severe
abdominal pain or diarrhoea, melena and hematochezia,
have to be interpreted as alarm signals requiring a
detailed examination. This is particularly important if
such symptoms occur in individuals with a family his-
tory of colorectal carcinoma (CRC) or other malignant
diseases or in individuals older than 50 years of age with
a lack of colonoscopy. In these individuals, malignant GI
diseases have to be excluded by appropriate means.
Moreover, other chronic GI diseases, such as GI
infections, GI immune diseases, inflammatory bowel dis-
ease (IBD), and antibiotic-associated diarrhoea, need to
be excluded.
Underlying mechanisms
The GI tract contributes to health in many ways. Multi-
ple data clearly indicate that the function of the gut is
by far not restricted to food processing and subsequent
nutrient and fluid uptake (Figure 1). Animal experi-
ments and some human data have shown that the gut
communicates with bacteria that support digestion by
their enzymatic capacity [11,12], that the gut regulates
major epithelial and immune functions of importance
for gut health and health in general [13,14] and that the
gut reports to the brain via the N. vagus and hormones
about energy uptake and other conditions that might
affect mood and general well-being [15]. The details of
how the gut has an impact on health in general have
been reviewed in detail elsewhere [1,11-15] and are
summarised in Figure 1. Of particular interest in this
context is the recent finding in germ-free mice that the
gut microbiota can directly influence not only GI func-
tions but also the development of behaviour and corre-
sponding neurochemical changes in the brain [16]. The
mechanisms of how the gut microbiota contributes to
gut health, however, are less clear.
There is now ample evidence that two functional enti-
ties are key to achieving and maintaining gut health
[17-20]. These entities are the GI microbiome and the
GI barrier, which is not just a mechanical barrier
assessed by some permeability measurements. Instead,
the current understanding of the GI barrier is more
complex, since it refers to a functional entity consisting
of epithelial defence and metabolic functions, the muco-
sal immune system and the enteric nervous system
(ENS). The importance of this zone in the context of
Table 1 Gut health and gastrointestinal health
a
Five major criteria for a healthy GI system Specific signs of GI health
Effective digestion and absorption of food Normal nutritional status and effective absorption of food, water and minerals
Regular bowel movement, normal transit time and no abdominal pain
Normal stool consistency and rare nausea, vomiting, diarrhoea, constipation and bloating
Absence of GI illness No acid peptic disease, gastroesophageal reflux disease or other gastric inflammatory disease
No enzyme deficiencies or carbohydrate intolerances
No IBD, coeliac disease or other inflammatory state
No colorectal or other GI cancer
Normal and stable intestinal microbiota No bacterial overgrowth
Normal composition and vitality of the gut microbiome
No GI infections or antibiotic-associated diarrhoea
Effective immune status Effective GI barrier function, normal mucus production and no enhanced bacterial translocation
Normal levels of IgA, normal numbers and normal activity of immune cells
Immune tolerance and no allergy or mucosal hypersensitivity
Status of well-being Normal quality of life
’Qi (ch’i)’, or positive gut feeling
Balanced serotonin production and normal function of the enteric nervous system
aGI, gastrointestinal; IBD, inflammatory bowel disease; IgA, immunoglobulin A.
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sampling and communication between host and luminal
content. Therefore, not only permeability tests, which
are known to have several serious limitations in them-
selves [21], but also the whole repertoire of tests record-
ing GI functions need to be considered for the
assessment of the GI barrier.
The GI microbiome consists of about 10
14 bacteria
that are mainly located in the large intestine [22,23].
Multiple functions of the GI microbiome have been
described (see Figure 2). The GI microbiome prevents
colonisation by potentially pathogenic microorganisms,
provides energy for the gut wall from undigested food
(for example, carbohydrates and other nutrients) and it
regulates the mucosal immune system, not only educat-
ing the naive infant immune system but also serving as
an important source of immune stimulators throughout
life [24-29]. Thus, the GI microbiota contributes to
energy homeostasis, prevents mucosal infections and
likely mitigates immune system hypersensitivity. Most
important, it contributes to the maintenance of an intact
GI barrier, which seems to be closely related to infec-
tious, inflammatory and allergic diseases [20,30].
Any impairment of the GI microbiome, for example,
by administration of oral antibiotics [31-33] or by an
unbalanced diet such as a carbohydrate-rich diet [34,35],
and SCB, (unpublished work), will affect the functional-
ity of the host’s local defence systems. On the other
hand, any malfunction of the epithelium, the immune
cells or the ENS will affect microbiota diversity and
functionality. In particular, the GI barrier, and conse-
quently gut health, will be directly altered not only by
local disturbances (such as increased epithelial perme-
ability due to infection or any loss of function of parti-
cular immune cells and their mediators) but also by any
systemic burden such as reduced oxygenation in inten-
sive care unit patients, malnutrition in cancer patients
and the elderly or altered nerve input because of
ongoing stress or depression [36-42]. Thus a normal GI
microbiota of rich diversity, as well as an intact GI bar-
rier that counteracts the bacteria and cooperates with
the commensal flora, is needed to maintain gut health.
The clinical consequences of such interrelationships
are only just beginning to be understood. For example,
antibiotic effects on gut microbiota composition and
functionality can now be assessed by novel GI microbiota
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Figure 1 The intestine’s impact on health. The gastrointestinal tract contributes to health by ensuring digestion and absorption of nutrients,
minerals and fluids; by induction of mucosal and systemic tolerance; by defence of the host against infectious and other pathogens; and by
signalling from the periphery to the brain. For details and references, see text ‘Underlying mechanisms’.
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been used to show that antibiotics such as ciprofloxacin
influence the abundance of about one-third of the bacter-
ial taxa in the gut, decreasing the taxonomic richness,
diversity and distribution of the flora. In all the indivi-
duals tested in one study [33], the taxonomic composi-
tion of the flora closely resembled its pretreatment state
four weeks after antibiotic treatment had finished, but
there were several taxa that failed to recover within six
months. These data conflict with prior assumptions that
ciprofloxacin has only a modest effect on the intestinal
microbiota. This example illustrates how quickly and
unintentionally the GI microbiota can be changed, and
we are just starting to realise the possible long-term con-
sequences of such manipulations. Further establishment
of diagnostic means to assess quickly and accurately the
GI microbiome composition using molecular techniques
will in the future allow us not only to describe in more
detail the multiple relationships between the colonic
microbiota and poor gut health but also to assess the
impact of interventions intended to restore a healthy
microbiota in the gut, such as dietary changes and the
administration of probiotics, prebiotics or antibiotics
[30,43,44].
The mucosal immune system of the GI tract both
controls the GI microbiome and depends on it. The per-
manent challenge of bacterial antigens to the mucosal
immune system is required for its normal development
and function [24,25]. In this context, it is not surprising
that the GI immune system contains cells capable of
recognising bacterial antigens by specific receptors, such
as T-cell receptors (TCRs) and B cell-derived, surface-
bound antibodies of the adaptive immune system, as
well as Toll-like receptors (TLRs) and other pattern
recognition receptors (PRRs) of the innate immune sys-
tem. Dendritic cells (via TLRs), lymphocytes (via TCRs
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Figure 2 Mechanisms of action of the intestinal microbiome on the gastrointestinal barrier. Commensal bacteria support the digestion of
fibres and other nutrients, thereby contributing to energy and substrate supply. They regulate epithelial functions such as mucus production in
goblet cells, defensin release from Paneth cells and tight junction protein synthesis in normal epithelial cells. They prevent colonisation of
pathogens in the gut and regulate the mucosal immune system, for example, by inducing and maintaining gut-associated lymphoid tissue and
by stimulating mucosal immunoglobulin A production. For details and references, see text ‘Underlying mechanisms’.
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phages and mast cells (via TLRs and other PRRs) are
also involved in communication between the GI micro-
biome and the GI immune system so that any danger
from pathogens can be recognised and also to maintain
the friendly coexistence of bacteria and host in the gut
[45-48].
To achieve the defence of the host against luminal
bacteria and other potentially harmful substances, the
GI immune system is equipped with specific tools, such
as the plasma cell-dependent immunoglobulin A (IgA)
defence system, goblet cell-derived mucus production
and the synthesis of antimicrobial peptides such as
defensins by Paneth cells [20,49-51]. All of these tools
play a part in controlling the GI microbiome and pro-
tecting the host against invasion of luminal bacteria
through the gut wall. Under normal conditions, these
mechanisms also prevent direct contact between com-
mensal bacteria and the GI epithelium [52]. Moreover,
the GI immune system allows regulation of inflamma-
tory responses to harmless antigens, such as food anti-
gens or bacterial antigens derived from commensals, by
mechanisms that together result in mucosal tolerance.
The details of these mechanisms are not fully under-
stood, but it is clear from numerous observations that
loss of bacterial challenge and loss of immune tolerance
results in severe hypersensitivity reactions, leading to
chronic inflammatory states such as allergic disease,
autoimmune disease and IBD [53,54]. Thus the GI
immune system contributes to both the defence against
and the acceptance of bacteria, and it fends off bacteria
yet also needs them, all of which illustrate the complex
balance of interactions between the GI microbiome and
t h eG Ii m m u n es y s t e mt h a tp r o t e c tt h eh o s ta n dm a i n -
tain gut health.
In addition to the mucosal immune system, the ENS is
another perplexing and complex control and defence
system that is starting to become understood. The ENS
contains 10
8 neurons and forms the largest neuronal
network outside the brain. It monitors luminal condi-
tions via sensory receptors and primary afferent neurons
activated by secretagogues from enterochromaffin cells
or mast cells such as biogenic amines (serotonin and
histamine) or proteases [55,56]. The ENS is strikingly
independent from the central nervous system (CNS), yet
it regulates almost all major functions of the gut, such
as epithelial secretion, absorption and permeability;
immune functions; and, as shown most recently, even
the GI microbiota [40,41]. GI infections, oral adminis-
tration of antibiotics and chronic diseases such as IBS
are clearly associated with morphological and functional
changes in the ENS, which emphasises its role in muco-
sal defence. The ENS mediates multiple as yet undefined
signals to the brain that seem to touch our awareness
only under pathological conditions. Recent experimental
studies strongly suggest that luminal conditions and sig-
nals, as well as the intestinal microbiota, are integrated
into a gut-brain axis (GBA). For example, the stress-
induced adrenocorticotropin hormone response in ani-
mals is much more pronounced in germ-free mice than
in colonised animals [57]. Such interrelationships might
provide a scientific basis for any ‘gut feeling’ or the
above-mentioned Asian understanding of the gut being
the centre of spiritual and physical strength. The first
hints that CNS diseases such as hepatic encephalopathy,
depression and autism spectrum disorder might be trea-
ted by modulating the GI microbiome (for example,
with the prebiotic and laxative lactulose, sugar-reduced
diets or antibiotics) is a further argument for the rele-
vance of the GBA [58-60]. Moreover, experimental data
have shown that probiotics, by modifying the GI micro-
biome, can affect both the ENS [61] and the CNS [62],
which highlights the relevance of the CNS for gut
health. Such findings might explain, at least in part, why
probiotics can show effects outside the GI tract.
The question of genetic factors that might influence
gut health is difficult to answer, because valid data are
lacking. Although a few IBS studies on familial asso-
ciations and gene polymorphisms have suggested that
genetic factors might play a role in the pathogenesis
of this disease [63,64], the converse argument that
genetic factors determine gut health is not justified
yet. In particular, polymorphisms have been examined
only in rather small groups, and familial associations
do not exclude that environmental factors, including
biological, psychological and sociological components,
also play a role. Moreover, apart from human gene
polymorphisms, bacterial genetic variations have to be
considered in this context [65]. Genetic and environ-
mental factors affecting gut health are not mutually
exclusive, since most chronic diseases, including
somatic syndromes and IBS, are likely related to both
[63,66]. In this context, it is interesting to note that
IBS is now also recognised from an epigenetic per-
spective on the basis of animal studies and a few
human data (reviewed in [67]). This emerging field
could in the future improve our understanding of how
diet and the gut microbiota might influence gut
health. Most excitingly, recent data in germ-free and
colonised mice indicate that commensal microbiota
profoundly shape the invariant natural killer T-cell
compartment, a major component of the host immune
system, through an epigenetic mechanism [68]. Other
groups have shown that selected bacterial strains can
induce regulatory cells that protect against pathogen-
triggered or allergen-induced inflammation [69]. Such
data strongly suggest that both genetic and epigenetic
factors are involved in the maintenance of gut health.
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awareness that the GI barrier consists of multiple
epithelial functions, the mucosal immune system, the
ENS as well as the tissue matrix, the muscle layers and
the blood supply. The GI barrier not only protects the
host against potential dangers from the GI lumen but
also allows food and liquid uptake, beneficial cross-talk
to commensal bacteria and immune tolerance against
harmless antigens. An intact GI barrier maintains gut
health, whereas disturbance of GI barrier functions is
increasingly recognised as an early but essential step in
the pathogenesis of many GI diseases and even extrain-
testinal diseases.
The GI microbiota and the GI barrier: implications for
disease
There is an ever-growing list of diseases for which
alterations of the GI barrier have emerged as a crucial
event in disease pathogenesis, and this list includes rele-
vant GI and extraintestinal diseases (Table 2). It is strik-
ing that many of these diseases are characterised by an
altered GI microbiota, further suggesting a link between
GI barrier function and GI microbiota composition.
The references cited in Table 2 demonstrate several
examples of an association between changes in micro-
biota and disease, although the mechanisms of interac-
tion are not always evident. On the other hand, because
of such associations, it is tempting to speculate that the
maintenance of normal microbiota and a stable GI bar-
rier contributes to gut health and likely to health in
general.
How to test gut health?
Gut health is frequently talked and written about but
rarely if ever measured, because the boundaries and
characteristics of this kind of ‘wellness’ are ill-defined.
Diagnostic efforts are mostly oriented towards measure-
ment of pathological situations, but the progress and
importance of preventive medicine makes assessment of
normal organ functions an increasingly relevant exercise.
To assess gut health, diagnostic methods must cover
both subjective complaints and objective parameters.
Complaints cannot be assessed without registering an
individual’s history by using a questionnaire or perform-
ing a structured personal dialogue, for example, with the
doctor. Questionnaires, ideally combined with some bio-
markers of prognostic relevance, are also appropriate to
screen a population and to accustom people to this par-
ticular issue, which is still often considered taboo. Such
an approach requires validated tools adapted to bowel-
related complaints and symptoms that would enable
clinicians to record improvements in well-being, quality
of life and prognosis in selected populations (Table 3).
One such questionnaire is the Inflammatory Bowel
Disease Questionnaire (IBDQ), a validated and reliable
tool used to measure health-related quality of life
(HRQoL) in adult patients with IBD, ulcerative colitis
and Crohn’s disease [70]. Whether the IBDQ can also
be used to assess HRQoL in the general population still
needs to be tested. One advantage of this questionnaire
is that it has been adapted and validated in several lan-
guages and cultural milieus. A more general tool is the
Bowel Disease Questionnaire (BDQ), which aims to dis-
tinguish patients with functional GI disease from those
with other conditions such as IBD or CRC [71]. Logistic
regression and discriminant analyses have shown that
the BDQ is a valid measure of symptoms of functional
GI disease. Probably the most suitable HRQoL assess-
ment tool is the Irritable Bowel Syndrome-Quality of
Life questionnaire, because IBS is the disease entity clo-
sest to the borderline between gut health and GI disease
[72]. The Health Status Questionnaire-12 (HSQ-12) is
another reliable, valid, low-cost measure of health status
that was created to assess the general population [73].
The HSQ-12, in contrast to the also validated 12-item
Short Form Health Survey (SF-12), can distinguish
between people with and without dementia [74]. On the
other hand, both the HSQ-12 and the SF-12 assess gen-
eral health status, but not specifically gut health. There-
fore, a short general questionnaire could be combined
Table 2 Diseases thought to be associated with GI barrier and GI microbiota
a
Location Diseases for which the GI barrier plays a central role in
pathogenesis
Diseases associated with an altered composition or function of
the GI microbiota
Intestinal Infectious diarrhoea [26,36]
Inflammatory bowel disease [130-132]
Coeliac disease [131]
Irritable bowel syndrome [133]
Inflammatory bowel disease [138,139]
Coeliac disease [140]
Irritable bowel syndrome [141,142]
Extraintestinal Allergic diseases [20,134,135]
Autoimmune diseases and arthritis [17]
Obesity, fatty liver disease and nonalcoholic steatohepatitis
(NASH) [35,136,137]
Systemic inflammatory response syndrome (SIRS) and sepsis in
ICU patients [36,37]
Malnutrition [40]
Allergic diseases [143,144]
Arthritis [145]
Obesity [125]
aGI, gastrointestinal; ICU, intensive care unit.
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a
Assessments and parameters Descriptions
Subjective assessments of well-being
Validated questionnaires useful to
assess quality of life and gut health
IBS-Quality of Life (IBS-QOL) Validated for assessment of quality of life specific to IBS: 34 questions
Inflammatory Bowel Disease
Questionnaire (IBDQ)
Validated for assessment of health-related quality of life (HRQoL) in adult
patients with IBD
Bowel Disease Questionnaire
(BDQ)
Validated to distinguish patients with functional and organic GI disease
Health Status Questionnaire (HSQ-
12)
Validated for assessment of HRQoL in the general population
Short Form Health Survey SF-12
(SF-12)
Validated for assessment of HRQoL in the general population
GI symptom scores IBS Severity Scoring System (IBS-
SSS)
Validated for scoring lower GI symptoms on the basis of nine questions;
range of 0 to 500 points
Short Form Leeds Dyspepsia
Questionnaire (SF-LDQ)
Validated instrument for measuring the presence and severity of dyspepsia
Gastrointestinal Symptom (GIS)
profile
Validated for assessment of symptoms of functional dyspepsia; 10
questions
Subject’s Global Assessment of
Relief (SGA)
Validated assessment of the impact of treatment on IBS-related symptoms;
1 question
IBS Global Assessment of
Improvement (IBS-GAI) ("adequate
relief”)
Asks participants if, compared to the way they felt before entering the
study, their IBS symptoms have changed over the past 7 days; 1 question
Functional Bowel Disorder
Severity Index (FBDSI)
Validated score for assessment of patient perception of abdominal pain in
IBS
Numeric Rating Scale (NRS) for
assessment of pain
Validated in IBS patients
Visceral Sensitivity Index (VSI) Validated psychometric instrument that measures GI symptom-specific
anxiety
Bristol Stool Scale/Bristol Stool
Chart
A medical aid designed to classify the form of human faeces into seven
categories
Gastrointestinal Symptom Rating
Scale
Eating habits Food frequency questionnaire 7-day diet history assessed using computer software
Objective parameters
Markers of functionality Gastric function pH metry in the esophagus [6,7] and stomach [1-3], gastroesophageal
reflux episodes (< 50/day, <60 minutes total), viscosity of the luminal
content using a viscometer, stool weight (> 100 g/d, <500 g/d) and stool
consistency (water content)
Permeability measurements Tracer molecules (lactulose/mannitol,
51Cr-EDTA, PEG);
Motility tests Barostat, gastric scintigraphy,
13C urea breath test (gastric emptying) and
lactulose hydrogen breath test (normal range: 40 to 240 hours)
Transit time Radiopaque pellets (Hinton test) and isotope-labelled test meal (normal
range: 24 to 168 hours)
Digestion parameters Stool elastase (> 200/g) and stool fat (< 7 g/d), carbohydrate breath tests,
anthropometry and micronutrient analysis
Markers of intestinal integrity Epithelial integrity Histology (villus height/crypt depth ratio, mitosis and apoptosis), mucus
secretion (mucins and trefoil peptides) and Ussing chamber (ion fluxes and
electric potentials)
Specific molecules E-cadherin, growth factors, tight junction molecules, a1-antitrypsin in faeces
and LPS in blood
Antimicrobial peptides a- and b-defensins, calprotectin, lysozyme or neutrophil-derived elastase in
faeces
Marker of intact immunity Cell counts and phenotyping Differential blood count and FACS analysis, histopathology of intestinal
biopsies and immunohistochemistry of intestinal biopsies
Cell mediators and cytokines Inflammatory cytokines (IL-1, IL-6 and TNFa), anti-inflammatory cytokines
(IL-10 and TGFb), regulatory cytokines (IL-2, sIL-2R, IL-4, IL-5 and so on),
proteases (tryptase, chymases, chymotrypsin and so on), immunoglobulins
(IgA, sIgA and IgE) and others (retinoic acid, neuropeptides and so on)
Bischoff BMC Medicine 2011, 9:24
http://www.biomedcentral.com/1741-7015/9/24
Page 7 of 14with a gut-related one, although this combination has
yet to be evaluated.
I tm a yb eh e l p f u lt oc o m b i n es u c hq u e s t i o n n a i r e s
with, for example, the Gastrointestinal Symptom Rating
Scale, consisting of 15 quest i o n so ns y m p t o m s[ 7 5 ] ,o r
the Bristol Stool Scale, which classifies the form of
human faeces into seven categories, with types 1 and 2
indicating constipation, types 3 and 4 being the ‘ideal
stools’, and types 5 to 7 suggesting diarrhoea or bowel
urgency [76]. Other disease-related GI symptom scales
that have been validated are the IBS Severity Scoring
System for scoring lower GI tract symptoms and the
Leeds Dyspepsia Questionnaire or the Gastrointestinal
Symptom profile for scoring upper GI tract symptoms
[77-79]. Moreover, scores have been developed and
tested which assess particular symptoms, such as pain,
using the Functional Bowel Disorder Severity Index or
the Numeric Rating Scale [80,81], as well as scores that
assess anxiety using the Visceral Sensitivity Index [82].
In clinical trials, overall improvement of symptoms has
been assessed by using singular global questions such as
the IBS Global Assessment of Improvement or the Sub-
ject’s Global Assessment of Relief, which have yielded
reliable results [83,84].
Bowel functions are extremely complex and variable;
therefore, objective assessment is a difficult task. Never-
theless, multiple approaches have been used to assess a
range of bowel functions. For example, glucose chal-
lenge with a subsequent hydrogen breath test was
believed to identify individuals with so-called ‘abnormal
bacterial colonisation’ of the intestine as a possible
cause of deterioration of gut health. Over the past few
years, there have been impressive developments in tech-
niques for analysing the human microbiome, such as
using metagenomic-metabonomic linkage analyses or
small subunit ribosomal RNA hypervariable tag sequen-
cing [7,30,43,44,85]. Microbiome analysis, however, is
still considered inappropriate for routine diagnosis of
gut function or gut health. However, even modern
molecular techniques do not yet allow the definition of
what can be considered a ‘normal’ or ‘optimal’ micro-
biome composition. On the other hand, an increasing
number of immunological parameters have become
available, among which cell counts and cell phenotyping
by flow cytometry and immunohistology and quantifica-
tion of cytokines, antibodies and mediators are the most
well-known tools (Table 3).
Despite an increasing number of more or less vali-
dated laboratory methods for objective assessment of
bowel function, the perception of the individual should
never be ignored. Only direct conversation between a
doctor and patient allows the opportunity of being able
to register GI-specific sensations that are pleasant,
which are primarily related to the intake of meals and
the evacuation of faeces, that is, gratifying sensations,
such as satiation and complete rectal evacuation. Other
physiological events, such as eructation and the emission
of wind from the anus, may also contribute to GI well-
being. Sensations related to thirst, taste, smell and the
desire of specific types of foods (salts or sweets, for
example) should also be considered part of this concept.
Patients with so-called functional GI diseases lose such
pleasant sensations, the perception of which will be
modulated by age, sex, cultural background and psycho-
logical stress.
How to maintain gut health?
Our knowledge about how to maintain or restore gut
health is limited in evidence-based medicine terms, but
general observations suggest that there is a wide range
of possible ways to support gut health and GI well-
being. Current medical research is much more focused
on the treatment of defined GI disease rather than on
the secondary or even primary prevention of disease.
For example, we know of several effective drugs to treat
acute IBD and a few to support remission, but almost
nothing to prevent IBD, a situation that might be related
not only to pathophysiological circumstances. On the
other hand, preventive medicine is increasingly per-
ceived as being important in medical and economic
terms, particularly in the field of gastroenterology,
w h e r ew eh a v et od e a lw i t hab r o a dg r e ya r e ab e t w e e n
suboptimal health and disease.
Many approaches to maintaining gut health and
preventing GI diseases such as infection, antibiotic-
associated diarrhoea, IBD, IBS, food allergy and so on
Table 3 Assessment of normal gut function
a (Continued)
Functional assays Cell cultures and cocultures, DTH response, phagocytosis, chemotaxis,
oxidative burst (superoxide anion generation) and NK cell activity
Analysis of the intestinal
microbiome
Classical approaches Bacterial culture and toxin measurements
New approaches Metagenomics (PCR and full bacterial sequencing), metabonomics
(metabolic capacity of the microbiome)
aIBS, irritable bowel syndrome; IBD, inflammatory bowel disease; GI, gastrointestinal;
51CR-EDTA, chromium ethylenediaminetetraacetic acid; PEG, polyethylene
glycol; LPS, lipopolysaccharide; FACS, fluorescence-activated cell sorting; IL, interleukin; TNF, tumour necrosis factor; TGF, transforming growth factor; sIL-2R,
soluble interleukin 2 receptor; Ig, immunoglobulin; sIgA, secretory immunoglobulin A; DTH, delayed-type hypersensitivity; NK, natural killer; PCR, polymerase chain
reaction.
Bischoff BMC Medicine 2011, 9:24
http://www.biomedcentral.com/1741-7015/9/24
Page 8 of 14are related to the hygiene hypothesis. This concept
maintains that any disturbance of the balance between
the microbiome and the mucosal immune system will
lead to impairment of the GI barrier and subsequently
to an increased risk to gut health and subsequent devel-
opment of GI disease [53,86-88]. Therefore, any condi-
tions that might disturb the intestinal microbiome and
the mucosal immune system should be avoided, such as
not only unbalanced diet and lack of exercise but also
extreme exercise and any type of chronic stress. In
recent publications, high-fat as well as high-fructose
diets have been shown to disturb the GI barrier and, in
this way, to induce fatty liver disease and subclinical
inflammatory conditions associated with metabolic dis-
turbances [35,89,90]. On the other hand, dietary changes
have been shown to help prevent major diseases such as
allergy, obesity and cancer [20,90,91]. Therefore, a
balanced diet that includes high vegetable and fibre con-
tent and moderate consumption of red meat to prevent
colon cancer [92,93], or an individualized elimination
diet in selected individuals with food intolerances, food
allergy or coeliac disease [94,95], might contribute to
gut health. Moreover, tobacco abstinence, moderate
alcohol consumption, maintenance of normal body
weight, avoidance of nonsteroidal anti-inflammatory
drug (NSAID) ingestion and control of stress can sup-
port gut health. Systematic strategies to improve lifestyle
and to avoid or reduce stress that have been validated in
controlled trials are rare; however, meditative methods
that often originate from traditional Chinese medicine
and other Asiatic cultures (for example, ayurveda and
tai-chi) are enjoying growing popularity and becoming
increasingly accepted by health professionals as valuable
tools to maintain gut health and general well-being
[96,97].
Chemoprevention by taking aspirin, cyclooxygenase 2
inhibitors and calcium may reduce the recurrence of
adenomas and/or the incidence of advanced adenomas
in individuals with an increased risk of CRC, and taking
aspirin may reduce the incidence of CRC in the general
population [98]. However, both aspirin and NSAIDs are
associated with adverse effects, so it will be important to
consider the risk-benefit ratio before recommending
these agents for chemoprevention. Other chemopreven-
tive strategies, such as retinoid-based therapy and
tumour necrosis factor-related, apoptosis-inducing
ligand in patients at risk for CRC, are based on animal
experiments and need to be confirmed in human studies
[99]. In the upper GI tract, chemopreventive strategies,
such as the use of celcoxib, have been shown to be less
successful [100]; therefore, endoscopic surveillance stra-
tegies are still indispensable in patients at risk for GI
malignancies.
An interesting idea is whether gut health can be
further supported by using modulators of the intestinal
microbiome or the GI barrier, such as probiotics or pre-
biotics. Indeed, it has been shown that chronic bowel
diseases such as IBD are associated with adherence of
commensal bacteria to the otherwise sterile intestinal
epithelium [101] and that selected probiotics can pre-
vent the adhesion of pathogenic bacteria to the intest-
inal mucosa [102] or restore leaky gut by improving the
molecular composition of tight junctions [103,104].
Moreover, probiotic bacteria can support the normal
development of the mucosal immune system, such as
through the C-C chemokine receptor 6 (CCR6)g e n e
expressed on lamina propria lymphocytes [24] and the
production of protective IgA and antimicrobial defensins
such as the CCR6 ligand human b-defensin 2 (or hBD2)
[105,106] that are both lacking in many chronic IBDs
[51]. These few selected examples indicate the strong
rationale for using probiotics, possibly also in synergistic
combinations with prebiotics, to maintain gut health.
We have good data now, even meta-analyses including
more than 1,000 individuals, on probiotic effects in pre-
venting or attenuating acute gastroenteritis, antibiotic-
associated diarrhoea, IBS and chronic constipation and
necrotising enterocolitis in small infants (reviewed in
[30]). Apart from this therapeutic approach, it is still dif-
ficult to give a general recommendation of probiotics as
a preventive measure. The number of prospective, con-
trolled human trials that have been conducted in this
field is rather small at present. Limited knowledge
within the scientific community and regulatory authori-
ties on suitable markers, as well as regarding the details
of how to perform such trials, is the main reason for the
lack of appropriate long-term, cost-intensive prevention
trials. Recently, a few trials have yielded promising but
rather preliminary clinical data or surrogate marker ana-
lysis [107-109]. The challenge for the future, based on
our growing expertise, is to select adequate measurable
parameters, to consider interindividual variations in the
composition of the intestinal microbiome and to exclude
numerous other putative confounding factors, since reg-
ulatory authorities require data from human trials, not
just for drugs but also for dietary supplements, to pro-
vide scientific support for health claims [1].
Outlook for gut health: a new objective in medicine?
Medicine in the Western world is undergoing substan-
tial changes. The more advances there are in treatment
options, the less affordable they become for everybody.
Breaking free of this vicious cycle requires effort not
only to manage advanced disease states but also to
intervene at an early stage. Only effective strategies in
preventive medicine keep our health systems affordable;
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nance of health, and this includes gut health [110-113].
One of the major areas that needs to be addressed is
the gut, because epidemiologic and economic data point
to the relevance of diseases such as IBS, IBD and CRC,
which are, in principle, to a large extent avoidable. So
far, great effort has been made to improve CRC preven-
tion strategies, with variable success [114,115]. The suc-
cess rate is limited less by the accuracy of the diagnostic
tools and more by dependence on the behaviour of a
population and the acceptance of screening programs.
Therefore, a major effort in the future must be made to
improve acceptance rates of guidelines by physicians
and of screenings by the afflicted populations [116].
M o r e o v e r ,t oi m p r o v eg u th e a l t h ,e f f o r t sm u s tn o tb e
restricted to malignant diseases such as CRC but must
also include inflammatory and so-called functional GI
diseases such as IBD and IBS.
Consideration of the overall burden and economic
impact of IBS, which afflicts perhaps 10% of the popula-
tion in a moderate to severe way, and almost everyone
from time to time at lower degrees, makes it clear that
every improvement in understanding IBS and care of
IBS is a positive step forward for gut health mainte-
nance [117]. There is now overwhelming evidence that
the intestinal microbiome is not only changed but also
involved in the pathogenesis of IBS and stress-induced
GI dysfunction [118,119]. Probiotic intervention, how-
ever, still needs to be improved [120,121]. We speak
about ‘good health’, and the bacteria that live in our gut
are said to be ‘in balance’ when the number of ‘good
bacteria’ outnumber the number of ‘bad bacteria’;h o w -
ever, we need to learn more about the mechanisms
underlying such expressions. Moreover, the mechanism
of activity for probiotics inside and beyond the gut is
also far from clear [122,123]. Overcoming these defi-
ciencies requires a new focus in research and the over-
coming of taboos that still exist for gut issues, which are
regarded as ‘ugly’ and ‘dirty’. The most relevant first
step would be to declare the maintenance of gut health
and the improvement of preventive medicine as major
goals in future medicine, which would have a positive
effect on people’s awareness, on research and education
and on health insurance coverage.
To focus on new gut health parameters such as micro-
biome gene analysis, and to combine them with tools
such as genomics and metabolomics, might become the
basis for a new kind of personalised medicine that nutri-
tionists and dieticians have been seeking for several
years [4-6,85]. Indeed, recent genome analysis of the
host has revealed that the success of dietetic recommen-
dations probably depends on the genetic makeup of the
individual [124]. Similar findings have been described by
microbiologists who found that obesity risk and
treatment response are associated with the particular
composition of the intestinal microbiome [125,126].
Possibly, gut health and general health are dependent
not only on the genetics of the host but also on the
genetics of the commensal bacteria. The tools required
to answer such questions are rapidly advancing and
have already allowed adequate analysis in research set-
tings and perhaps also in the near future in health care
settings [1,27]. The use of such tools in daily practice
for diagnostic purposes and for new drug development
[127], together with improved communication about gut
issues as proposed by several national initiatives in the
United Kingdom [128], the Netherlands [129] and
Germany (initiative of the Felix-Burda foundation; see
http://www.darmgesundheits-check.de/), would likely
improve both our understanding of gut health and our
approaches to maintaining it. By doing so, an exciting
new contribution to preventive, therapeutic and more
economically efficient medical practice could be offered.
Summary
The term ‘gut health’ has become popular; however,
from a scientific point of view, the term is poorly
defined and used in different contexts. It covers all
aspects, ranging from the Asian understanding of the
gut as the middle of spiritual and physical strength to
the Western understanding of the GI barrier as a central
body site interacting with the environment and involved
in the pathophysiology of many intestinal and extrain-
testinal diseases. The expression ‘gut health’ lacks clear
definition in the scientific literature, although it has
been used repeatedly in human medicine and in animal
health. Herein a positive definition of ‘gut health’ is pro-
posed in accordance with the WHO definition of health:
‘Gut health is a state of physical and mental well-being
in the absence of gastrointestinal complaints that
require the consultation of a doctor, in the absence of
indications or risks of bowel disease, and in the absence
of confirmed bowel disease’ (source: Constitution of the
World Helath Organization, New York 1946, see http://
www.who.int/governance/eb/who_constitution_en.pdf).
The relevance of gut health is underlined by the fact
that its loss is characterised by a large variety of symp-
toms, often prompting an individual to consult a doctor.
Such symptoms are associated with the widespread dis-
ease IBS and comprise flatulence, bloating, regurgitation,
heartburn, nausea, vomiting, constipation, diarrhoea,
food intolerance, incontinence, abdominal pain and
cramps, loss of appetite, weight loss and blood in stools.
Functional oesophageal and gastric diseases must also
be considered in this context. In most cases, such symp-
toms reflect more or less harmless diseases that might
a f f e c tq u a l i t yo fl i f eb u tn o tm o r t a l i t y .S o m eo ft h e
symptoms, however, such as anorexia, unintended
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Page 10 of 14weight loss, dysphagia, continuing vomiting, severe
abdominal pain or diarrhoea, melena and hematochezia,
must be interpreted as alarm signals requiring a detailed
examination. This is particularly important if such
symptoms occur in individuals with a family history
of CRC or in older adults who have never had a
colonoscopy.
The mechanisms of ensuring gut health are complex
and comprise a healthy lifestyle, a balanced diet, normal
GI perfusion, normal GI microbiome and likely a stable
mental status. Any major impairment of these mechan-
isms leads to a breakdown of the GI barrier that defends
us against environmental and endogenous hazards. Of
particular interest in this context is a better understand-
ing of the interaction between the GI microbiome and
the mucosal immune system, which both depend on
each other to form an intact GI barrier. Moreover, mul-
tiple epithelial functions, apart from nutrient absorption,
and functions of the enteric nervous system seem to be
of crucial importance to maintaining a functional GI
barrier and ultimately gut health. The measurement of
gut health is not well established. Two approaches have
been recognised: assessment of subjective complaints by
using validated questionnaires indicating gut health and
assessment of physiological GI function by defining and
measuring validated biomarkers related to gut health.
Both approaches are equivalent and cannot replace each
other.
Gut health can offer a new approach to preventive
medicine if we learn more about how to achieve and
maintain it. Current medical research is much more
focused on the treatment of defined GI diseases rather
than on the secondary or even primary prevention of
disease. However, preventive medicine is increasingly
perceived as being important in medical and economic
terms, particularly in the field of gastroenterology.
Therefore, scientifically justified approaches to maintain-
ing gut health and to preventing GI diseases are wel-
come. Although this is an area with many open
questions, we have started to learn that lifestyle charac-
teristics, such as balanced diet, moderate but regular
exercise and avoidance of chronic stress, but also
defined products such as select pre- and probiotics, can
support gut health. This topic will concern us even
more in the future if we succeed at increasing our
knowledge of the underlying mechanisms and how to
influence them in a positive way.
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